ELTX

Elicio Therapeutics, Inc.

Healthcare
Biotechnology
$36M market cap

Forecast run · Oct 30, 2026Upside rank 64 of 3,167

Model Signal

ForecastQ Daily Probabilities

71.2%

46.5%

63.8%

Analyst Consensus

Recommendation2.50/5 Buy

Last price$1.90

Price target$11.83

Implied move+522.6%

Analysts4

ForecastQ Portfolios

Microcap Short Microcap Short signal →

Company Profile

Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.